NCT05388058View on ClinicalTrials.gov

Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy

PHASE2CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

June 9, 2022

Primary Completion Date

July 14, 2023

Study Completion Date

July 28, 2023

Conditions
Chemotherapy-Induced Peripheral NeuropathyMalignant Solid Neoplasm
Interventions
DRUG

Cannabidiol

Applied topically

DRUG

Placebo Administration

Applied topically

OTHER

Quality-of-Life Assessment

Ancillary studies

OTHER

Questionnaire Administration

Ancillary studies

Trial Locations (9)

55362

Monticello Cancer Center, Monticello

55371

Fairview Northland Medical Center, Princeton

55744

Fairview Grand Itasca Clinic and Hospital, Grand Rapids

55746

Fairview Range Medical Center, Hibbing

55905

Mayo Clinic in Rochester, Rochester

56001

Mayo Clinic Health System Mankato, Mankato

56007

Mayo Clinic Health System Albert Lea, Albert Lea

56187

Sanford Worthington, Worthington

56701

Sanford Thief River Falls, Thief River Falls

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
lead

Mayo Clinic

OTHER

NCT05388058 - Topical Cannabidiol for the Treatment of Chemotherapy-Induced Peripheral Neuropathy | Biotech Hunter | Biotech Hunter